Posteromedial Tibial Bone Bruise After Anterior Cruciate Ligament Injury: An MRI Study of Bone Bruise Patterns in 208 Patients von Byrd, Jennifer M., Colak, Ceylan, Yalcin, Sercan, Winalski, Carl, Briskin, Isaac, Farrow, Lutul D., Jones, Morgan H., Miniaci, Anthony A., Parker, Richard D., Rosneck, James T., Saluan, Paul M., Strnad, Gregory J., Spindler, Kurt P.

Volltext

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab von Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

Volltext

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation von Buhimschi, Alexandru D, Armstrong, Haley A, Toure, Momar, Jaime-Figueroa, Saul, Chen, Timothy L, Lehman, Amy M, Woyach, Jennifer A, Johnson, Amy J, Byrd, John C, Crews, Craig M

Volltext

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia von Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R

Volltext

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results von Byrd, John C., Wierda, William G., Schuh, Anna, Devereux, Stephen, Chaves, Jorge M., Brown, Jennifer R., Hillmen, Peter, Martin, Peter, Awan, Farrukh T., Stephens, Deborah M., Ghia, Paolo, Barrientos, Jacqueline, Pagel, John M., Woyach, Jennifer A., Burke, Kathleen, Covey, Todd, Gulrajani, Michael, Hamdy, Ahmed, Izumi, Raquel, Frigault, Melanie M., Patel, Priti, Rothbaum, Wayne, Wang, Min Hui, O'Brien, Susan, Furman, Richard R.

Volltext

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma von Munir, Talha, Brown, Jennifer R., O'Brien, Susan, Barrientos, Jacqueline C., Barr, Paul M., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Kipps, Thomas J., Moreno, Carol, Montillo, Marco, Burger, Jan A., Byrd, John C., Hillmen, Peter, Dai, Sandra, Szoke, Anita, Dean, James P., Woyach, Jennifer A.

Volltext

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib von Woyach, Jennifer A, Furman, Richard R, Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S, Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M, Versele, Matthias, Dave, Sandeep S, Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M, Blum, Kristie A, Lozanski, Arletta, Lozanski, Gerard, James, Danelle F, Barrientos, Jacqueline C, Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J, Chang, Betty Y, Johnson, Amy J, Byrd, John C

Volltext

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chro... von Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Ferrant, Emmanuelle, Wierda, William G., Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, Byrd, John C.

Volltext

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL von Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., Byrd, John C.

Volltext

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia von Woyach, Jennifer A, Ruppert, Amy S, Guinn, Daphne, Lehman, Amy, Blachly, James S, Lozanski, Arletta, Heerema, Nyla A, Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L, McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A, Flynn, Joseph M, Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A, Awan, Farrukh T, Blum, Kristie A, Grever, Michael R, Lozanski, Gerard, Johnson, Amy J, Byrd, John C

Volltext

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL von Woyach, Jennifer A, Ruppert, Amy S, Heerema, Nyla A, Zhao, Weiqiang, Booth, Allison M, Ding, Wei, Bartlett, Nancy L, Brander, Danielle M, Barr, Paul M, Rogers, Kerry A, Parikh, Sameer A, Coutre, Steven, Hurria, Arti, Brown, Jennifer R, Lozanski, Gerard, Blachly, James S, Ozer, Hatice G, Major-Elechi, Brittny, Fruth, Briant, Nattam, Sreenivasa, Larson, Richard A, Erba, Harry, Litzow, Mark, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S, Little, Richard F, Smith, Scott E, Stone, Richard M, Mandrekar, Sumithra J, Byrd, John C

Volltext

Accurate Predictions of Crystal Densities Using Quantum Mechanical Molecular Volumes von Rice, Betsy M, Hare, Jennifer J, Byrd, Edward F. C

Volltext

Acalabrutinib in treatment-naive chronic lymphocytic leukemia von Byrd, John C., Woyach, Jennifer A., Furman, Richard R., Martin, Peter, O'Brien, Susan, Brown, Jennifer R., Stephens, Deborah M., Barrientos, Jacqueline C., Devereux, Stephen, Hillmen, Peter, Pagel, John M., Hamdy, Ahmed, Izumi, Raquel, Patel, Priti, Wang, Min Hui, Jain, Nitin, Wierda, William G.

Volltext

Second cancer incidence in CLL patients receiving BTK inhibitors von Bond, David A., Huang, Ying, Fisher, James L., Ruppert, Amy S., Owen, Dwight H., Bertino, Erin M., Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Jaglowski, Samantha M., Maddocks, Kami J., Byrd, John C., Woyach, Jennifer A.

Volltext

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 tri... von Sharman, Jeff P, Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M, Flinn, Ian W, Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A, Salles, Gilles, Wierda, William G, Izumi, Raquel, Munugalavadla, Veerendra, Patel, Priti, Wang, Min Hui, Wong, Sofia, Byrd, John C

Volltext

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia von Woyach, Jennifer A, Blachly, James S, Rogers, Kerry A, Bhat, Seema A, Jianfar, Mojgan, Lozanski, Gerard, Weiss, David M, Andersen, Barbara L, Gulrajani, Michael, Frigault, Melanie M, Hamdy, Ahmed, Izumi, Raquel, Munugalavadla, Veerendra, Quah, Cheng, Wang, Min-Hui, Byrd, John C

Volltext

Age-Specific Incidence of Melanoma in the United States von Paulson, Kelly G, Gupta, Deepti, Kim, Teresa S, Veatch, Joshua R, Byrd, David R, Bhatia, Shailender, Wojcik, Katherine, Chapuis, Aude G, Thompson, John A, Madeleine, Margaret M, Gardner, Jennifer M

Volltext

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia von Herman, Sarah E M, Montraveta, Arnau, Niemann, Carsten U, Mora-Jensen, Helena, Gulrajani, Michael, Krantz, Fanny, Mantel, Rose, Smith, Lisa L, McClanahan, Fabienne, Harrington, Bonnie K, Colomer, Dolors, Covey, Todd, Byrd, John C, Izumi, Raquel, Kaptein, Allard, Ulrich, Roger, Johnson, Amy J, Lannutti, Brian J, Wiestner, Adrian, Woyach, Jennifer A

Volltext

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients von Brown, Jennifer R, Byrd, John C, Ghia, Paolo, Sharman, Jeff P, Hillmen, Peter, Stephens, Deborah M, Sun, Clare, Jurczak, Wojciech, Pagel, John M, Ferrajoli, Alessandra, Patel, Priti, Tao, Lin, Kuptsova-Clarkson, Nataliya, Moslehi, Javid, Furman, Richard R

Volltext

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia von Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., Furman, Richard R.

Volltext